sunitinib "mylan" 25 mg kapsler, hårde
mylan ab - sunitinib - kapsler, hårde - 25 mg
sunitinib "mylan" 37,5 mg kapsler, hårde
mylan ab - sunitinib - kapsler, hårde - 37,5 mg
sunitinib "mylan" 50 mg kapsler, hårde
mylan ab - sunitinib - kapsler, hårde - 50 mg
sunitinib "sandoz" 37,5 mg kapsler, hårde
sandoz a/s - sunitinib - kapsler, hårde - 37,5 mg
sunitinib "stada" 25 mg kapsler, hårde
stada arzneimittel ag - sunitinib - kapsler, hårde - 25 mg
sunitinib "stada" 50 mg kapsler, hårde
stada arzneimittel ag - sunitinib - kapsler, hårde - 50 mg
sunitinib "zentiva" 37,5 mg kapsler, hårde
zentiva k.s. - sunitinib - kapsler, hårde - 37,5 mg
opzelura
incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - andre dermatologiske præparater - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
cibinqo
pfizer europe ma eeig - abrocitinib - dermatitis, atopisk - andre dermatologiske præparater - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.
inlyta
pfizer europe ma eeig - axitinib - carcinom, nyrecelle - protein kinase hæmmere - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.